LOADING
Comparing Johnson & Johnson (JNJ) and Pfizer Inc (PFE), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | PFE |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $537.4B | $144.4B |
| P/E Ratio | 25.8 | 19.3 |
| Forward P/E | 19.3 | 8.6 |
| PEG Ratio | 2.90 | 13.77 |
| EPS | $8.64 | $1.31 |
| Revenue Growth (YoY) | 9.9% | 5.4% |
| Profit Margin | 21.8% | 11.8% |
| Return on Equity | 26.4% | 8.3% |
| Dividend Yield | 2.33% | 6.73% |
| Beta | 0.26 | 0.30 |
| 52-Week High | $250.24 | $28.28 |
| 52-Week Low | $145.39 | $21.73 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Pfizer Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.